| # | Drug | Count |
|---|---|---|
| 0 | INFLIXIMAB | 388 |
| 1 | ADALIMUMAB | 355 |
| 2 | METHOTREXATE SODIUM | 322 |
| 3 | METHOTREXATE | 304 |
| 4 | ETANERCEPT | 290 |
| 5 | PREDNISONE | 285 |
| 6 | SULFASALAZINE | 273 |
| 7 | TOCILIZUMAB | 269 |
| 8 | ANAKINRA | 235 |
| 9 | ABATACEPT | 234 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AMLODIPINE BESYLATE VALSARTAN HYDROCHLOROTHIAZIDE | 1 | 0.0244 |
| 1 | VACCINIA IMMUNE GLOBULIN INTRAVENOUS (HUMAN) | 2 | 0.0227 |
| 2 | VELMANASE ALFA-TYCV | 1 | 0.0179 |
| 3 | IOBENGUANE I-123 | 2 | 0.0175 |
| 4 | ANAKINRA | 235 | 0.0139 |
| 5 | CEFOTETAN DISODIUM | 1 | 0.0089 |
| 6 | ALGLUCOSIDASE ALFA | 20 | 0.0082 |
| 7 | NAXITAMAB | 2 | 0.0080 |
| 8 | CEFOTETAN | 1 | 0.0075 |
| 9 | DINUTUXIMAB | 5 | 0.0058 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 454 |
| 1 | Corticosteroid [EPC] | 357 |
| 2 | Folate Analog Metabolic Inhibitor [EPC] | 305 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 301 |
| 4 | Aminosalicylate [EPC] | 279 |
| 5 | Interleukin-6 Receptor Antagonist [EPC] | 269 |
| 6 | Interleukin-1 Receptor Antagonist [EPC] | 235 |
| 7 | Selective T Cell Costimulation Modulator [EPC] | 234 |
| 8 | Vitamin B12 [EPC] | 100 |
| 9 | Vitamin C [EPC] | 99 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-1 Receptor Antagonist [EPC] | 235 | 0.0139 |
| 1 | Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] | 20 | 0.0058 |
| 2 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 6 | 0.0055 |
| 3 | Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] | 35 | 0.0036 |
| 4 | Human Immunoglobulin G [EPC] | 75 | 0.0036 |
| 5 | Aminosalicylate [EPC] | 279 | 0.0028 |
| 6 | Interleukin-6 Receptor Antagonist [EPC] | 269 | 0.0019 |
| 7 | Selective T Cell Costimulation Modulator [EPC] | 234 | 0.0017 |
| 8 | Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] | 8 | 0.0011 |
| 9 | Thrombopoietin Receptor Agonist [EPC] | 14 | 0.0009 |